Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Other Non Operating Income (2020 - 2025)

Avalo Therapeutics' Other Non Operating Income history spans 5 years, with the latest figure at -$3000.0 for Q3 2025.

  • For Q3 2025, Other Non Operating Income rose 40.0% year-over-year to -$3000.0; the TTM value through Sep 2025 reached -$13000.0, down 160.0%, while the annual FY2024 figure was -$5000.0, 88.1% up from the prior year.
  • Other Non Operating Income reached -$3000.0 in Q3 2025 per AVTX's latest filing, up from -$5000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of -$3000.0 in Q3 2025 to a low of -$40000.0 in Q2 2023.
  • Average Other Non Operating Income over 4 years is -$14500.0, with a median of -$10000.0 recorded in 2021.
  • Peak YoY movement for Other Non Operating Income: crashed 178.95% in 2021, then surged 70.59% in 2024.
  • A 4-year view of Other Non Operating Income shows it stood at -$15000.0 in 2021, then dropped by 13.33% to -$17000.0 in 2023, then skyrocketed by 70.59% to -$5000.0 in 2024, then soared by 40.0% to -$3000.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Other Non Operating Income are -$3000.0 (Q3 2025), -$5000.0 (Q2 2025), and -$5000.0 (Q3 2024).